Stronger together: Stabilizing the interactions between HCV E1 and E2 for vaccines

J. Capella Pujol

Stronger together: Stabilizing the interactions between HCV E1 and E2 for vaccines

J. Capella Pujol

Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

Abstract

Hepatitis C virus (HCV) infection places a major burden on global health, affects 50 million people and causes 250,000 yearly deaths. Yet, there is no HCV vaccine available. The only target for neutralizing antibodies against HCV is the E1E2 glycoprotein on the virion surface. Eliciting broadly neutralizing antibodies that recognize conserved cross-neutralizing epitopes is important for an

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Amsterdam
Supervisors/Advisors	Sanders, Rogier, Supervisor Sliepen, Kwinten, Co-supervisor Schinkel, Janke , Co-supervisor
Award date	27 Jun 2025
Print ISBNs	9789464963793
Publication status	Published - 2025

Access to Document

https://hdl.handle.net/11245.1/0e431b8d-3e1a-4ea5-a29f-5c094ddb0f1e

Cite this

@phdthesis{d2cf9097444448e4939fd104bc8a57bd,

title = "Stronger together: Stabilizing the interactions between HCV E1 and E2 for vaccines",

abstract = "Hepatitis C virus (HCV) infection places a major burden on global health, affects 50 million people and causes 250,000 yearly deaths. Yet, there is no HCV vaccine available. The only target for neutralizing antibodies against HCV is the E1E2 glycoprotein on the virion surface. Eliciting broadly neutralizing antibodies that recognize conserved cross-neutralizing epitopes is important for an",

author = "\{Capella Pujol\}, J.",

year = "2025",

language = "English",

isbn = "9789464963793",

type = "Phd-Thesis - Research and graduation internal",

school = "University of Amsterdam",

}

TY - THES

T1 - Stronger together

T2 - Stabilizing the interactions between HCV E1 and E2 for vaccines

AU - Capella Pujol, J.

PY - 2025

Y1 - 2025

N2 - Hepatitis C virus (HCV) infection places a major burden on global health, affects 50 million people and causes 250,000 yearly deaths. Yet, there is no HCV vaccine available. The only target for neutralizing antibodies against HCV is the E1E2 glycoprotein on the virion surface. Eliciting broadly neutralizing antibodies that recognize conserved cross-neutralizing epitopes is important for an

AB - Hepatitis C virus (HCV) infection places a major burden on global health, affects 50 million people and causes 250,000 yearly deaths. Yet, there is no HCV vaccine available. The only target for neutralizing antibodies against HCV is the E1E2 glycoprotein on the virion surface. Eliciting broadly neutralizing antibodies that recognize conserved cross-neutralizing epitopes is important for an

M3 - Phd-Thesis - Research and graduation internal

SN - 9789464963793

ER -

Stronger together: Stabilizing the interactions between HCV E1 and E2 for vaccines

Abstract

Access to Document

Fingerprint

Cite this